Talcum Powder Lawsuit: Where the $5.5B Settlement Stands

Johnson & Johnson has spent close to a decade trying to resolve tens of thousands of lawsuits alleging its talc-based products, primarily baby powder, caused ovarian cancer. Three attempts to move that liability into a bankruptcy filing all failed. In July 2026, the company announced a $5.5 billion settlement negotiated directly in the tort system instead — but “announced” and “final” are not the same fact, and this page exists to keep that distinction clear rather than let it blur, the way a lot of coverage of this case understandably does.

Quick answer: The federal litigation is MDL No. 2738 before Judge Michael A. Shipp in the District of New Jersey, with roughly 68,000 pending cases. On July 27, 2026, J&J disclosed (in an SEC filing) a $5.5 billion settlement covering the MDL and related state-court cases, using a tiered, uncapped compensation structure rather than one divided fund. It is conditioned on 95% claimant participation and is not yet finalized — an initial payment of up to $3 billion is projected for 2027, with nothing further before 2028. This follows three separate, failed attempts by a J&J subsidiary to resolve the same claims through Chapter 11 bankruptcy.

Three Failed Bankruptcy Attempts: The “Texas Two-Step”

Rather than defend tens of thousands of individual lawsuits, a J&J subsidiary tried a maneuver nicknamed the Texas Two-Step: split off the talc liability into a newly created entity, then have that entity — not the profitable parent company — file for Chapter 11 bankruptcy, where claims are typically resolved for far less than a jury might award.

• First attempt — LTL Management. Rejected on appeal; the Third Circuit Court of Appeals found the subsidiary was not in genuine financial distress and had been created for the filing itself.
• Second attempt — LTL Management, refiled. Also unsuccessful in ultimately resolving the claims through bankruptcy.
• Third attempt — Red River Talc, filed September 20, 2024. A Texas bankruptcy judge rejected the filing on March 31, 2025, after a two-week trial, ruling that the company could not use bankruptcy to resolve tort claims where the underlying business was not actually insolvent. J&J stated it would not appeal and would return to negotiating individual and consolidated settlements in the ordinary tort system.

That history matters for reading the current settlement correctly: it followed three failed attempts to pay a smaller amount through a bankruptcy process, not an isolated decision.

What the July 2026 Settlement Actually Says

Per J&J’s own Form 8-K filed with the SEC on July 27, 2026:

• $5.5 billion total, intended to resolve the MDL and related state-court cases — reported as covering roughly 76,000 remaining claims, close to 99.75% of the pending caseload.
• Conditioned on 95% claimant participation. This is a real contingency, not a formality — the deal is structured so J&J can walk away if too many plaintiffs opt to continue litigating instead.
• A tiered, uncapped compensation grid, not one lump fund divided evenly. Individual payouts are meant to scale with the specifics of each claim rather than everyone receiving an identical or pro-rata share.
• Payment timeline: an initial payment of up to $3 billion projected for 2027, with no further payments before 2028.

None of this is the same as “the settlement is final” or “checks are being distributed.” Confirming that 95% participation figure, and whatever court approval process applies to the settlement structure, is the actual work happening now.

What Counts as a Claim

Two distinct injury tracks exist within this litigation, and they are not interchangeable:

• Ovarian cancer, alleged to result from long-term perineal (genital) use of talc-based powder products — this is the large majority of claims in MDL 2738.
• Mesothelioma, alleged to result from asbestos contamination within talc products — a smaller, separately evaluated set of claims, because the causation evidence (asbestos fiber exposure) and typical case value differ substantially from the ovarian cancer claims.

An attorney evaluating a potential claim will generally want the specific cancer diagnosis, history and duration of product use, and any product-purchase or usage documentation you can locate — receipts, product packaging, or even a family member’s recollection of brand and duration of use, since these products were often used for decades before diagnosis. Once this settlement is actually finalized and funded, see our guide to filing a claim in a mass tort settlement for how the claim form, documentation and deadline process generally works.

Reading Any “Settlement Update” With Care

This litigation is a useful case study in the caution our guide to how mass tort litigation actually works describes: a settlement announcement is not a settlement event. Before this deal, this same litigation saw three different bankruptcy filings characterized in the moment as likely to resolve the claims — all three failed. That doesn’t mean this settlement will fail too, but it is a specific, documented reason to verify current status rather than assume a July 2026 announcement is still accurate reporting by the time you’re reading this. J&J is not the only company to try this maneuver, and not the only one to fail at it — see our guides to the Purdue Pharma opioid settlement and the 3M Combat Arms earplug litigation for two more companies whose subsidiary or third-party bankruptcy filings were also rejected before a settlement was ultimately reached a different way.

Sources & Further Reading

• U.S. District Court, District of New Jersey — official case page for In re: Johnson & Johnson Talcum Powder Products Marketing, Sales Practices, and Products Liability Litigation, MDL No. 2738
• Johnson & Johnson, Form 8-K, filed with the SEC on July 27, 2026 — the company’s own disclosure of the settlement terms
• In re: LTL Management LLC, Third Circuit Court of Appeals — rejecting the initial “Texas Two-Step” bankruptcy filing
• In re: Red River Talc LLC, U.S. Bankruptcy Court (S.D. Texas) — March 31, 2025 ruling rejecting the third bankruptcy attempt
• See our explainer on how mass tort litigation actually works for what “MDL,” “bellwether trial” and “global settlement” mean in practice, and personal injury lawyer fees for how attorneys are typically paid in this kind of case
• To check which of the active litigations your own exposure and diagnosis line up with, use our mass tort eligibility screener